Literature DB >> 6094420

Newer beta-lactam antibiotics in the treatment of experimental Staphylococcus aureus endocarditis.

V K Dhawan, H Thadepalli, M K Maier, M Nayyar, M B Bansal, S K Chuah.   

Abstract

Antistaphylococcal activity of three beta-lactam antibiotics, i.e. cefmenoxime, cefotaxime and latamoxef (moxalactam) was compared with that of nafcillin by studying cure rates of aortic valvular endocarditis caused by one of three clinical isolates of Staphylococcus aureus in New Zealand white male rabbits. The animals were randomly allocated to a control and four antibiotic treatment groups. Each animal except the controls received 60 mg/kg of one antibiotic intramuscularly twice daily for two weeks, beginning 24 h after induction of endocarditis. The aortic valve was sterilized in 11 of 15 (73%) animals treated with cefmenoxime, nine of 13 (69%) treated with cefotaxime, 11 of 13 (85%) treated with latamoxef and 12 of 15 (80%) treated with nafcillin. All nine animals in the control group developed aortic valvular vegetations with an average of 2.4 X 10(9) cfu/g. The differences in sterility rates resulting from treatment with the four antibiotics were not statistically significant (P greater than 0.70).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6094420     DOI: 10.1093/jac/14.2.165

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  Microbiological investigation of cephalosporins.

Authors:  J M Hamilton-Miller
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Efficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis.

Authors:  Joan Gavaldà; Pedro López; Teresa Martín; Xavier Gomis; José Luis Ramírez; Carlos Azuaje; Benito Almirante; Albert Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 3.  Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.